Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...

Trial shows GRI-0621 improved lung function with signs of fibrosis resolution GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic ...

LA JOLLA, CA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...

BELAY Inc. December 9, 20253 min read ATLANTA, GEORGIA / ACCESS Newswire/ December 9, 2025 / BELAY, the leading provider of flexible staffing solutions, announced today its acquisition of Fully ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The focus is on centers anchored ...

Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...

GRI Bio Inc.’s oral version of tazarotene is showing phase IIa promise in idiopathic pulmonary fibrosis (IPF). The peek at interim safety with the compound, a RAR-βɣ dual agonist designed to inhibit ...

Behind the Line is Foobooz’s interview series with the people who make up Philly’s dynamic bar and restaurant scene. For the complete archives, go here. Close to two years after Heather Thomason’s ...

Saudi Arabian World Cup climber Sara Qunaibet was the victim of improper use of a Petzl GriGri by a professional coach. She suffered two broken feet and a broken back but could have easily died, ...

Joel Carboni, President of GPM Global is a pioneer in advancing sustainable practices for organizations in both projects and operations. As a sustainability executive and a standards writer, I have ...